Elevation Oncology Stock Forum

$Elevation Oncology (ELEV.US)$ when will you squeeze

$Elevation Oncology (ELEV.US)$
Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2

$Elevation Oncology (ELEV.US)$ Second Quarter 2024 Financial Results
As of June 30, 2024, Elevation Oncology had cash, cash equivalents and marketable securities totaling $110.8 million, compared to $83.1 million as of December 31, 2023. The increase in cash reflects net proceeds of $44.2 million, which Elevation Oncology raised through its at-the-market (ATM) facility in the first half of 2024, partially offset by cash used to fund operating activities

$Elevation Oncology (ELEV.US)$ -- Elevation Oncology to host conference call and webcast today at 8:30 a.m. ET

$Elevation Oncology (ELEV.US)$ nice

$Elevation Oncology (ELEV.US)$  Data expected readout of EO-3021 data in the latter half of 2024, which could showcase the efficacy and safety of the anti-Claudin 18.2 antibody-drug conjugate in treating advanced cancers.
Furthermore, preclinical data has shown that Elevation Oncology’s HER3-ADC candidate demonstrates significant antitumor activity, suggesting a strong foundation for future clinical evaluations

Hello Mooers!
A quick recap for the month ending April 30, 2024.
Ten stocks with >300% YTD
$Swvl Holdings (SWVL.US)$718.40%
$Root Inc (ROOT.US)$564.60%
$Elevation Oncology (ELEV.US)$561.08%
$JanOne (JAN.US)$554.05%
$GeneDx Holdings (WGS.US)$520.71%
$Corbus Pharmaceuticals (CRBP.US)$513.25%
$AGBA Group (AGBA.US)$482.90%
$Janux Therapeutics (JANX.US)$431.22%
$Dave Inc (DAVE.US)$4...

$Elevation Oncology (ELEV.US)$
NEWS
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
Elevation Oncology announces promising preclinical data for its HER3-ADC program, showcasing proof-of-concept results at AACR Annual Meeting 2024. The data demonstrates HER3-dependent cell killing and robust anti-tumor activity in solid tumors with high HER3 expression. The company aims to nominate a development candidate later in 2024.

$Elevation Oncology (ELEV.US)$ $Merrimack Pharmaceuticals (MACK.US)$   Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan
MT Newswires· 2 mins ago
Merrimack Pharmaceuticals (MACK) said late Wednesday it has received a $225 million milestone payment from Ipsen and called for a special stockholder meeting on May 10 to approve a plan of dissolution.
The milestone payment was due from Ipsen after the US Food and Drug Administration approved Onivyde as a first-line...

$Elevation Oncology (ELEV.US)$ Elevation Oncology Announced That It Has Expanded Its Ongoing Phase 1 Clinical Trial Of EO-3021 Outside The United States, Dosing The First Patient In Japan